Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Dr Marc Laniado made a choice to be more mindful of his own health - here's what he discovered, from 'exercise snacking' to ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...

Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.

Across the UK, pub bells will ring early for the final time this Wednesday as part of a new campaign by Greene King and Macmillan Cancer Support ...

Microplastics have now been found inside most prostate cancer tumors — and at strikingly higher levels than in healthy tissue.

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...